ArticleJournal of traditional and complementary medicine2025
Zhongfeng Xingnao prescription alleviates injury of intracerebral hemorrhage via regulating the CaMKII/NF-κB p65/NLRP3/GSDMD signaling axis.
Article in Journal of traditional and complementary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis of the Influence of Integrated Traditional Chinese and Western Medicine on Cognitive Dysfunction After Hypertensive Intracerebral Hemorrhage.Brain and behavior · 2025Pooled it
- Therapeutic Potential of Traditional Chinese Herbal Medicines in Intracerebral Haemorrhage: A Narrative Review.Neurology and therapy · 2026Review
- YiQi-HuoXue prescription ameliorates LPS-induced sepsis-associated encephalopathy via VCAM-1-mediated microglial efferocytosis.Frontiers in immunology · 2026Article
- MPTP mediated Ox-mtDNA release inducing macrophage pyroptosis and exacerbating MCD-induced MASH via promoting the ITPR3/CaJournal of translational medicine · 2025Article
- Selected traditional Chinese medicine interventions for post-stroke cerebral edema: a review integrating clinical evidence and mechanistic insights.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: The NLRP3 inflammasome can be activated after intracerebral hemorrhage (ICH), triggering an inflammatory response in the brain. Chinese herbal medicine Zhongfeng Xingnao Prescription (ZFXN) is commonly used in China for intracerebral hemorrhage treatment. However, the underlying treatment mechanism of it is unclear. The purpose of our study is to investigate whether ZFXN alleviates injury after intracerebral hemorrhage by blocking the activation of CaMKII/NF-κB p65/NLRP3/GSDMD signaling axis. Experimental procedure: We evaluated the protective effect of ZFXN in a rat model of collagenase Ⅶ-induced ICH. The neurological deficit score, cerebral hematoma-injury ratio, pathology, and ultrastructure of tissue surrounding the hematoma were evaluated after 5 days of ZFXN treatment, CaMKII/NF-κB p65/NLRP3/GSDMD signaling axis-related protein expression around the hematoma was assessed by Western blot and immunohistochemistry. Meanwhile, ELISA measured the levels of IL-1β, IL-18, IL-6 and TNF-α in serum. Results and conclusion: After 5 days of ZFXN treatment, the score of neurological deficit and hematoma damage ratio decreased, and the cell destruction such as edema and vacuole conditions around the hematoma improved. The mechanism investigation results showed that ZFXN down-regulated expressions of CaMKII/NF-κB p65/NLRP3/GSDMD signaling axis-related protein around the hematoma area. In addition, ZFXN could attenuate the inflammatory response by regulating the activation of NLRP3 inflammasome after ICH. For the first time, we found that the efficacy of ZFXN on ICH might be related to the regulation of NLRP3 inflammasome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.